Skip to main content
See every side of every news story
Published • loading... • Updated

MSD Stops Trials of BTK Inhibitor for Blood Cancers

Merck said an independent monitoring committee found the drug’s benefits may not outweigh its risks, ending two other late-stage trials.

Summary by Pharmaphorum
MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.

9 Articles

ReutersReuters
Reposted by
regionalmedianews.comregionalmedianews.com
Center

Merck stops trials of blood cancer drug after review of risks

·London, United Kingdom
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Reuters broke the news in London, United Kingdom on Tuesday, November 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal